drugset / Trial / NCT07184450
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-03-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA/CD70-targetd CAR-T | Cell therapy | 0.3 cells/kg | Intravenous |
| Subject | BCMA/CD70-targetd CAR-T | Cell therapy | 1 cells/kg | Intravenous |
| Subject | BCMA/CD70-targetd CAR-T | Cell therapy | 3 cells/kg | Intravenous |